The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of second-line lenvatinib after progression on immunotherapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis.
 
Tarek Arabi
No Relationships to Disclose
 
Abdullah Alruwaili
No Relationships to Disclose
 
Mohamed Aseafan
No Relationships to Disclose
 
Fahad Almugbel
No Relationships to Disclose
 
Muhammad Shahzad Rauf
No Relationships to Disclose
 
Ahmed Alzahrani
No Relationships to Disclose
 
Ali Aljubran
No Relationships to Disclose
 
Shouki Bazarbashi
Honoraria - AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Hikma; Ipsen; Lilly; Merck Serono; Merck Sharp & Dohme; Newbridge Pharmaceuticals; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; HIKMA; Ipsen; Merck KGaA; Merck Sharp & Dohme; pfizer; Roche; Taiba
Research Funding - Astellas Pharma (Inst); Kite/Gilead (Inst); Lilly; Merck KGaA (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Hikma Pharmaceuticals; Ipsen; Janssen; Merck; SERVIER
 
Ali Alqahtani
No Relationships to Disclose